Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Karyopharm Therapeutics Inc. (KPTI) had Revenue of $145.24M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$145.24M
Net Income	$-76.42M
Cost of Goods Sold	$6.01M
Gross Profit	$139.23M
Operating Expenses	$264.68M
Operating Income	$-119.44M
Non-Operating Income/Expense	$43.08M
Pre-Tax Income	$-76.36M
Normalized Pre-Tax Income	$-76.36M
Income after Taxes	$-76.42M
Income from Continuous Operations	$-76.42M
Consolidated Net Income/Loss	$-76.42M
Normalized Income after Taxes	$-76.42M
EBIT	$-119.44M
EBITDA	$-115.24M
Weighted-Average Shares Outstanding (Basic)	8.13M
Weighted-Average Shares Outstanding (Diluted)	8.46M
Earnings per Share (EPS) (Basic)	$-9.45
Earnings per Share (EPS) (Diluted)	$-13.94
Balance Sheet Financials
Current Assets	$156.49M
Property, Plant, and Equipment	$0.40M
Long-Term Assets	$7.93M
Total Assets	$164.42M
Current Liabilities	$92.26M
Long-Term Debt	$162.95M
Long-Term Liabilities	$258.17M
Total Liabilities	$350.44M
Common Equity	$-186.02M
Tangible Shareholders Equity	$-186.02M
Shareholders Equity	$-186.02M
Common Shares Outstanding	8.42M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-127.49M
Cash Flow from Investing Activities	$95.47M
Cash Flow from Financial Activities	$41.65M
Beginning Cash	$53.19M
End Cash	$62.81M
Increase/Decrease in Cash	$9.62M
Stock-Based Compensation	$18.43M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.70
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-7.06
Debt to Equity Ratio	-1.01
Gross Margin	95.86%
Operating Margin	-82.24%
EBIT Margin	-82.24%
EBITDA Margin	-79.34%
Pre-Tax Profit Margin	-52.58%
Profit Margin	-52.62%
Free Cash Flow	$-127.63M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.88
Inventory Turnover	1.27
Receiveable Turnover	4.72
Days Sales in Receivables	77.32
Return on Equity	41.08%
Return on Tangible Equity	41.08%
Return on Assets	-46.48%
Return on Investments	331.28%
Book Value Per Share	$-22.10
Free Cash Flow per Share	$-15.09
Operating Cash Flow per Share	$-15.07

Data from Zacks Investment Research, Inc.